SCHEDULE: Tang Capital Discloses 11.3% Stake in Boundless Bio
Schedule 13G Filing
Tang Capital Management, LLC and affiliated entities have reported beneficial ownership of 11.3% of Boundless Bio, Inc.'s common stock.
Summary
- Tang Capital Management, LLC, along with Kevin Tang and other affiliated entities (Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; and Tang Capital Partners IV, Inc.), has filed a Schedule 13G.
- This filing indicates beneficial ownership of 2,533,845 shares of Boundless Bio, Inc. common stock.
- This represents 11.3% of the total outstanding shares.
- The filing states that these shares were not acquired for the purpose of influencing control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on existing beneficial ownership without new financial performance data or strategic announcements.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Management Comments
- The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.
Industry Context
StockSavvy.ai notes that this Schedule 13G filing by Tang Capital Management and its affiliates signifies a significant passive investment in Boundless Bio, Inc., indicating a substantial stake without immediate intentions to control the company. Such filings often precede or follow strategic shifts or market interest in a particular biotechnology firm.
Stakeholder Impact
- Shareholders: The filing provides transparency regarding a significant ownership stake by Tang Capital, which may influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 06/15/2026 | Date as of which the number of outstanding shares of Common Stock was set forth in the Form 8-K. |
| 06/23/2026 | Date of filing of the Form 8-K referenced for outstanding share count. |
| 06/23/2026 | Date of Event Which Requires Filing of this Statement (Schedule 13G). |
| 06/29/2026 | Date of signatures on the Schedule 13G and Joint Filing Agreement. |
Keywords
Schedule 13G, Boundless Bio, Tang Capital Management, Beneficial Ownership, SEC Filing, Common Stock, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.